EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight

Xiaosu Ma, Ying Grace Li, Sohini Raha, David C Sperry, David E Coutant, Shobha Bhattachar

Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 5803-5809

DOI: 10.1111/dom.70783 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.04.2026. Verfasst von Xiaosu Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity, Overweight. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the bioequivalence of orally administered orforglipron tablets and capsules in participants with obesity or overweight who were otherwise healthy. Materials and Methods This phase 1, multicenter, open‐label, multiple‐dose, dose‐escalation study was conducted in 429 healthy adults. Study participants received each orforglipron capsule and tablet dose strength once daily for 7 days in the fasted state at capsule doses of 1, 3, 6, 12, 24, or 36 mg and corresponding tablet doses of 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg. The primary endpoint was steady‐state area under the concentration–time curve from 0 to 24 h (AUC 0–24,ss ) and steady‐state maximum observed drug concentration ( C max,ss ). A prespecified mixed scaling approach was applied to evaluate bioequivalence. Safety and tolerability of the tablets and capsules were also assessed.

Results

Bioequivalence was demonstrated between capsules and dose‐adjusted tablets across all six doses. The 90% confidence interval of the ratios of the geometric least‐squares means of AUC 0–24,ss and C max,ss between each capsule dose and corresponding tablet dose met the predefined criteria for bioequivalence. The safety profiles were similar between tablets and capsules, with no apparent differences or trends in the incidence of treatment‐emergent adverse events by presentation or with increasing dose.

Conclusions

Once‐daily orforglipron capsules and dose‐adjusted tablets demonstrated pharmacokinetic bioequivalence at all tested doses and showed similar safety and tolerability profiles, with mostly mild treatment‐emergent adverse events consistent with previous orforglipron clinical trials. ClinicalTrials .gov Identifier: NCT06440980.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsObesityOverweightAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralArea Under CurveCapsulesDose-Response Relationship, DrugTabletsTherapeutic EquivalencyOxadiazolesFluorine Compounds

Stichwörter der Autor:innen

GLP‐1antiobesity drugobesity therapypharmacokinetics

Substanzen

Anti-Obesity AgentsCapsulesorforglipronTabletsOxadiazolesFluorine Compounds

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, Indiana, USA.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Ma, X., Li, Y. G., Raha, S., Sperry, D. C., Coutant, D. E., & Bhattachar, S. (2026). Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight. Diabetes, Obesity and Metabolism, 28(7), 5803-5809. https://doi.org/10.1111/dom.70783

Vancouver

Ma X, Li YG, Raha S, Sperry DC, Coutant DE, Bhattachar S. Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight. Diabetes, Obesity and Metabolism. 2026;28(7):5803-5809. doi:10.1111/dom.70783

BibTeX
@article{Ma2026,
  author = {Ma, Xiaosu and Li, Ying Grace and Raha, Sohini and Sperry, David C and Coutant, David E and Bhattachar, Shobha},
  title = {Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {7},
  pages = {5803--5809},
  doi = {10.1111/dom.70783}
}
Kostenlos starten →